{"success":true,"data":{"pressRelease":{"id":"159527","rtpr_id":"nGNXchcvmk-20261002","ticker":"CRSP","exchange":"NASDAQ","all_tickers":["CRSP"],"title":"CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026","author":"Globe Newswire","published_at":"2026-10-02T14:15:00.129Z","article_body":"ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR\nTherapeutics (Nasdaq: CRSP), today announced that a poster presentation\nhighlighting the Company’s Phase 1 clinical data of its investigational\nCRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel\n(zugo-cel) targeting CD19 for autoimmune disease, will be presented at the\nAmerican College of Rheumatology (ACR) Convergence 2026.\n\nTitle: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor\n(CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with\nRefractory Systemic Sclerosis\nSession Type: Poster Presentation\nAbstract Number: 0225\nSession Name: Poster Session A\nDate and Time: Sunday, November 8, 2026, 10:30 a.m. ET\n\nZugo-cel is being evaluated in Phase 1 trials across autoimmune diseases,\nincluding rheumatologic, hematologic and neurologic indications.\n\nA copy of the presentation will be available at www.crisprtx.com once the\npresentation concludes.\n\nAbout CRISPR Therapeutics\nCRISPR Therapeutics is a leading biopharmaceutical company focused on\ndeveloping transformative gene-based medicines for serious human diseases.\nFounded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the\nCompany has evolved from a pioneering research-stage organization into an\nindustry leader, marking a historic milestone with the approval of\nCASGEVY(®) (exagamglogene autotemcel [exa-cel]), the world’s first\nCRISPR-based therapy, for eligible patients with sickle cell disease and\ntransfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is\nadvancing a broad, diversified pipeline spanning hemoglobinopathies,\ncardiovascular disease, autoimmune disease, oncology, regenerative medicine\nand rare diseases. The Company is also expanding its gene editing toolkit\nthrough SyNTase™ editing, its novel, proprietary platform designed to enable\nprecise, efficient, and scalable gene correction. To accelerate its impact,\nCRISPR Therapeutics has established strategic collaborations with leading\nbiopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR\nTherapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned\nU.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in\nBoston, Massachusetts and San Francisco, California. To learn more,\nvisit www.crisprtx.com.\n\nCRISPR THERAPEUTICS(®) standard character mark and design logo and\nSyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics\nAG. CASGEVY(®) and the CASGEVY logo are registered trademarks of Vertex\nPharmaceuticals Incorporated. All other trademarks and registered trademarks\nare the property of their respective owners. \n\nCRISPR Therapeutics Forward-Looking Statement\nStatements contained in this press release regarding matters that are not\nhistorical facts are “forward-looking statements” within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Because such statements\nare subject to risks and uncertainties, actual results may differ materially\nfrom those expressed or implied by such forward-looking statements. Such\nstatements include, but are not limited to, statements regarding any or all of\nthe following: (i) CRISPR Therapeutics preclinical studies, clinical trials\nand pipeline products and programs, including, without limitation,\nmanufacturing capabilities, status of such studies and trials and expectations\nregarding data, safety and efficacy generally; (ii) data included in the\nabove-described poster presentation and any associated abstract; and (iii) the\ntherapeutic value, development, and commercial potential of gene editing\ntechnologies and therapies, including CRISPR/Cas9, as well as other\ntechnologies. Risks that contribute to the uncertain nature of the\nforward-looking statements include, without limitation, the risks and\nuncertainties discussed under the heading “Risk Factors” in CRISPR\nTherapeutics most recent annual report on Form 10-K and in any other\nsubsequent filings made by CRISPR Therapeutics with the U.S. Securities and\nExchange Commission. Existing and prospective investors are cautioned not to\nplace undue reliance on these forward-looking statements, which speak only as\nof the date they are made. We disclaim any obligation or undertaking to update\nor revise any forward-looking statements contained in this press release,\nother than to the extent required by law.\n\nInvestor Contact: \n+1-617-307-7503 \nir@crisprtx.com\n\nMedia Contact: \n +1-617-315-4493 \nmedia@crisprtx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5dac7d0d-131d-4047-bab7-db8e0719bf58)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXchcvmk-20261002","title":"CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026","author":"Globe Newswire","ticker":"CRSP","created":"2026-10-02T14:15:00.129Z","tickers":["CRSP"],"exchange":"NASDAQ","article_body":"ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR\nTherapeutics (Nasdaq: CRSP), today announced that a poster presentation\nhighlighting the Company’s Phase 1 clinical data of its investigational\nCRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel\n(zugo-cel) targeting CD19 for autoimmune disease, will be presented at the\nAmerican College of Rheumatology (ACR) Convergence 2026.\n\nTitle: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor\n(CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with\nRefractory Systemic Sclerosis\nSession Type: Poster Presentation\nAbstract Number: 0225\nSession Name: Poster Session A\nDate and Time: Sunday, November 8, 2026, 10:30 a.m. ET\n\nZugo-cel is being evaluated in Phase 1 trials across autoimmune diseases,\nincluding rheumatologic, hematologic and neurologic indications.\n\nA copy of the presentation will be available at www.crisprtx.com once the\npresentation concludes.\n\nAbout CRISPR Therapeutics\nCRISPR Therapeutics is a leading biopharmaceutical company focused on\ndeveloping transformative gene-based medicines for serious human diseases.\nFounded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the\nCompany has evolved from a pioneering research-stage organization into an\nindustry leader, marking a historic milestone with the approval of\nCASGEVY(®) (exagamglogene autotemcel [exa-cel]), the world’s first\nCRISPR-based therapy, for eligible patients with sickle cell disease and\ntransfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is\nadvancing a broad, diversified pipeline spanning hemoglobinopathies,\ncardiovascular disease, autoimmune disease, oncology, regenerative medicine\nand rare diseases. The Company is also expanding its gene editing toolkit\nthrough SyNTase™ editing, its novel, proprietary platform designed to enable\nprecise, efficient, and scalable gene correction. To accelerate its impact,\nCRISPR Therapeutics has established strategic collaborations with leading\nbiopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR\nTherapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned\nU.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in\nBoston, Massachusetts and San Francisco, California. To learn more,\nvisit www.crisprtx.com.\n\nCRISPR THERAPEUTICS(®) standard character mark and design logo and\nSyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics\nAG. CASGEVY(®) and the CASGEVY logo are registered trademarks of Vertex\nPharmaceuticals Incorporated. All other trademarks and registered trademarks\nare the property of their respective owners. \n\nCRISPR Therapeutics Forward-Looking Statement\nStatements contained in this press release regarding matters that are not\nhistorical facts are “forward-looking statements” within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Because such statements\nare subject to risks and uncertainties, actual results may differ materially\nfrom those expressed or implied by such forward-looking statements. Such\nstatements include, but are not limited to, statements regarding any or all of\nthe following: (i) CRISPR Therapeutics preclinical studies, clinical trials\nand pipeline products and programs, including, without limitation,\nmanufacturing capabilities, status of such studies and trials and expectations\nregarding data, safety and efficacy generally; (ii) data included in the\nabove-described poster presentation and any associated abstract; and (iii) the\ntherapeutic value, development, and commercial potential of gene editing\ntechnologies and therapies, including CRISPR/Cas9, as well as other\ntechnologies. Risks that contribute to the uncertain nature of the\nforward-looking statements include, without limitation, the risks and\nuncertainties discussed under the heading “Risk Factors” in CRISPR\nTherapeutics most recent annual report on Form 10-K and in any other\nsubsequent filings made by CRISPR Therapeutics with the U.S. Securities and\nExchange Commission. Existing and prospective investors are cautioned not to\nplace undue reliance on these forward-looking statements, which speak only as\nof the date they are made. We disclaim any obligation or undertaking to update\nor revise any forward-looking statements contained in this press release,\nother than to the extent required by law.\n\nInvestor Contact: \n+1-617-307-7503 \nir@crisprtx.com\n\nMedia Contact: \n +1-617-315-4493 \nmedia@crisprtx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5dac7d0d-131d-4047-bab7-db8e0719bf58)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-02T14:15:00.167935668Z","server_sent_at_ms":1790950500167},"received_at":"2026-10-02T14:15:00.218Z","source_url":null},"analysis":{"id":"148126","press_release_id":"159527","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"CRISPR Therapeutics will present Phase 1 data on zugo-cel, its CRISPR/Cas9 gene-edited allogeneic anti-CD19 CAR T therapy for autoimmune disease, in a poster at ACR Convergence 2026 on November 8.\n\nThe poster covers safety and efficacy in patients with refractory systemic sclerosis, one of several Phase 1 autoimmune indications spanning rheumatologic, hematologic and neurologic areas.\n\nNo new data were disclosed in this announcement; it is a scheduling notice ahead of the conference.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Watch for actual zugo-cel autoimmune data release on November 8 rather than this scheduling notice."},"keyFigures":{"drugName":"zugocabtagene geleucel (zugo-cel)","phaseOfTrial":"Phase 1","customDimensions":{"abstract_number":"0225","presentation_date":"2026-11-08"}},"namedEntities":{"people":[],"products":["zugo-cel (zugocabtagene geleucel)","CASGEVY (exa-cel)","SyNTase"],"companies":[{"name":"CRISPR Therapeutics","ticker":"CRSP","relationship":"filer"},{"name":"Vertex Pharmaceuticals","relationship":"collaboration partner"},{"name":"American College of Rheumatology","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference poster-presentation announcement; no new data disclosed in the release itself. Phase 1 asset, early-stage, standard pre-conference PR."},"tickerRelevance":{"others":[],"primary":"CRSP"},"globalImportance":20,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap-biotech","eventGravity":"conference-presentation-announcement","issuerAuthored":true,"retailFavoriteBoost":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"CRISPR Therapeutics will present Phase 1 data on zugo-cel, its CRISPR/Cas9 gene-edited allogeneic anti-CD19 CAR T therapy for autoimmune disease, in a poster at ACR Convergence 2026 on November 8.\n\nThe poster covers safety and efficacy in patients with refractory systemic sclerosis, one of several Phase 1 autoimmune indications spanning rheumatologic, hematologic and neurologic areas.\n\nNo new data were disclosed in this announcement; it is a scheduling notice ahead of the conference.","key_figures":{"drugName":"zugocabtagene geleucel (zugo-cel)","phaseOfTrial":"Phase 1","customDimensions":{"abstract_number":"0225","presentation_date":"2026-11-08"}},"named_entities":{"people":[],"products":["zugo-cel (zugocabtagene geleucel)","CASGEVY (exa-cel)","SyNTase"],"companies":[{"name":"CRISPR Therapeutics","ticker":"CRSP","relationship":"filer"},{"name":"Vertex Pharmaceuticals","relationship":"collaboration partner"},{"name":"American College of Rheumatology","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T14:15:04.647Z","global_importance":20,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap-biotech","eventGravity":"conference-presentation-announcement","issuerAuthored":true,"retailFavoriteBoost":true}},"durationMs":4360,"modelName":"glm-5.3-flashx"}}